就在今天！

南京江北新区生物医药谷园区企业

先声药业鸣响上市金锣

正式登陆港交所

我们共同期待先声药业未来在发展中

继续创造新的辉煌

2020年10月27日，先声药业集团有限公司（香港交易所股份代号：2096.HK）今日宣布，正式在香港交易所挂牌上市。先声药业本次全球发售2.61亿股，预计募集资金净额约33.9亿港元。

October 27, 2020 - Simcere Pharmaceutical Group Limited (2096.HK) announced today that the company has officially been listed on the Hong Kong Stock Exchange. The total global offering is 261 million shares, with net proceeds expected to reach approximately HK$3.39 billion.

先声药业是一家从事药品研发、生产和商业化的公司，正快速向创新驱动转型。我们聚焦的治疗领域包括肿瘤（含细胞治疗）、中枢神经系统及自身免疫疾病，拥有多元化的产品组合。在南京、上海、波士顿建有三个研发中心，并获批建设“转化医学与创新药物国家重点实验室”。曾于2007年登录纽约证券交易所，是当时国内第一家赴纽交所上市的化学生物药公司， 2013年完成私有化。

Simcere Pharmaceutical Group Limited is a company engaged in the R&D, production and commercialization of pharmaceuticals, and we are currently undergoing a rapid transition towards being an innovation-driven pharmaceutical company. Our diversified product portfolio is strategically focused on several key therapeutic areas, including oncology (including cell therapy), central nervous system diseases and autoimmune diseases. They have established three R&D centers in Nanjing, Shanghai and Boston, and have been approved to build a "State Key Laboratory of Translational Medicine and Innovative Drug Development" in China. We became the first Chinese chemical and biological pharmaceutical company listed on the New York Stock Exchange in 2007, and went private in 2013.

今天，我们重回资本市场。

上市仪式上，公司创始人、董事长兼首席执行官任晋生表示：

“对创业公司而言，最重要的是敢于从零开始、创造新事业的勇气，以及敢于向不可能挑战、面对困难不断前行的精神。

今天，先声回归资本市场，值得我和同事们保持冷静、认真思考。我们将持续加大研发投入，拒绝任何浮躁和急功近利心态，向领先者学习。

‘一个人走得更快，一群人走得更远’，先声要远行，就应该吸引和凝聚更多力量，信任伙伴，善于合作，坚定地朝着同一个目标，互相搀扶，群策群力，一路向前。”

Seven years after going private, today we are returning to the capital market. 

Attending the company’s listing ceremony, Mr. Ren Jinsheng, founder, Chairman and CEO of Simcere said: 

To start and run a company successfully, the key factor is the spirit - the courage to start from scratch and establish a brand new business. It is the determination to challenge the impossible and move forward in face of any difficulties.

Today we are returning to the capital market. I'd like to avail this opportunity to think deeply of the meaning it conveys. We shall continue to put investment in R&D, rather than being impetuous or eager for instant benefits. We must learn from the leading runners.

 “If you want to go fast, go alone; if you want to go far, go with others.“ Simcere is aiming for long-term goals. Therefore, we must gather together to make joint efforts so as to move further toward the same goal.

近年来，先声药业的营业总收入由2017年的人民币38.68亿元增加至2019年的50.37亿元，年复合增长率为14.1%

In recent years, company revenue has increased from RMB 3.868 billion in 2017 to RMB 5.037 billion in 2019, with a compound annual growth rate of 14.1%. 

先声药业的研发投入占营收比重由2017年的5.5%上升至2019年的14.2%，2020年上半年达23.6%。目前，先声药业拥有十余种占据市场领先地位的产品，其中包括三个I类新药和一个进口创新药。

At the same time, the company’s ratio of R&D investments to revenue has steadily increased from 5.5% in 2017 to 14.2% in 2019, and in the first half of 2020, the ratio reached 23.6%. Currently, Simcere has launched more than 10 types of products with leading positions in their respective markets, including three category I innovative drugs in China and one imported innovative pharmaceutical. 

2020年，先声药业新获批上市两款创新药产品：与BMS合作开发的治疗类风湿关节炎的生物药恩瑞舒®（阿巴西普注射液）和自主研发的脑卒中神经保护治疗新药先必新®（依达拉奉右莰醇注射用浓溶液）。

In 2020, Simcere launched two innovative products. Developed in collaboration with Simcere’s overseas partner BMS, Orencia®(Abatacept Injection) was introduced into China by Simcere as a new biological drug for the treatment of rheumatoid arthritis. Meanwhile, Sanbexin® (Edaravone and Dexborneol Concentrated Solution for Injection) is a category I innovative pharmaceutical developed in-house by Simcere to treat acute cerebral infraction.

此外，先声药业与康宁杰瑞、思路迪医药签订合作协议，获得一款可皮下注射PD-L1抑制剂KN035在中国的肿瘤适应症独家商业化权益，该项目正在中国进行dMMR/MSI-H结直肠癌及其他晚期实体瘤的II期临床试验及晚期胆道癌III期临床试验。与此同时，先声的研发管线中还有近50种处于不同研发阶段的创新药物。

In addition, They have obtained the exclusive promotion rights in China regarding oncology treatment indications of a PD-L1 inhibitor known as KN035. Our partners Jiangsu Alphamab and 3D Medicines are currently conducting Phase II clinical trials of KN035 for dMMR/MSI-H colorectal carcinoma and other advanced solid tumors, Phase III clinical trials for advanced BTC on Chinese mainland and Phase I clinical trials in the United States and Japan. Beyond these exciting developments, Simcere is also overseeing the development of nearly 50 other innovative pharmaceuticals, all at various stages in our R&D pipeline.

此次在港交所上市募集的资金主要用于：重点治疗领域在研产品的研发，加强销售及营销能力，投资拥有重大商业价值及有望解决未满足医疗需求的医药或生物技术公司，从而拓宽产品组合，偿还贷款等用途。

Through this global offering, They intend to use the raised capital over the next few years for several key areas. This includes continuing our R&D work towards select product candidates among our therapeutic areas of strategic focus, reinforcing the company’s sales and marketing capabilities, and investing in other pharmaceutical or biotech companies with significant commercial value and expected to meet the medical needs, with a view to broadening the product portfolio, as well as the repayment of certain bank loans.

再次上市，对于先声人来说，比获得更多资源投入研发更重要的是保持初心和创业精神，继续奉行长期主义和群体奋斗，让患者早日用上更有效药物。

We view the return of Simcere to the stock market as a major milestone. It will not only help us attract more resource for R&D, but even more importantly serve as a powerful reminder to us all to keep in mind the company’s original aspiration and entrepreneurial spirit. As such, we plan to keep working hard as a group and for the long term, and thereby realize the goal of “Providing Today's Patients with Medicines of the Future.”

素材来源：先声药业